-
2024-517422-25-00
5
2025-05-22
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2024-511495-32-00
5
2025-04-16
Chronic Phase Chronic Myeloid Leukemia
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-512960-75-00
5
2025-02-04
Resectable Non-small cell lung cancer
-
2023-504899-25-00
5
2024-04-04
Metastatic castration resistant prostate cancer
-
2022-502113-28-00
5
2024-02-01
Follicular lymphoma
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2023-508302-24-00
4
2019-05-07
Locally Advanced/Metastatic Urothelial Cancer
-
2022-502706-33-00
6
2018-01-10
Patients with invasive breast cancer in early stages
-
2024-516909-23-00
4
2025-10-28
Locally Advanced Resectable Gastroesophageal Adenocarcinoma
-
2023-508276-11-00
5
2025-01-17
Gastric cancer, Advanced/Metastatic Gastric cancer, Gastroesophageal J
-
2023-506668-15-00
5
2024-06-17
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2023-508359-38-00
5
2024-06-05
Early-stage Non-squamous Non-small Cell Lung Cancer
-
2023-504541-31-00
5
2024-03-06
Myelodysplastic syndrome
-
2023-507448-36-00
5
2024-02-16
Non-small Cell Lung Cancer
-
2022-500802-16-00
5
2023-11-01
Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung
-
2024-518486-10-00
4
2023-02-23
Non-Muscle Invasive Bladder Cancer
-
2023-509429-37-00
5
2022-10-03
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2023-507933-12-00
5
2022-08-18
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
-
2023-509516-28-00
4
2021-02-22
Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III col
-
2023-507338-26-00
5
2021-02-01
Histologically documented gastric or gastroesophageal junction adenoca
-
2024-514604-14-00
4
2019-09-18
Muscle-invasive bladder cancer
-
2022-501485-22-00
5
2018-12-18
Myelodysplastic syndrome (MDS)
-
2023-506112-40-00
5
2018-09-26
R/R Multiple Myeloma